dailypolitical.com
Positivewww.dailypolitical.com ·
diamedica therapeutics nasdaqdmac releases quarterly earnings results misses expectations by 0 02 eps
TAX_FNCACT_ANALYSTSTAX_DISEASE_STROKEEPU_ECONOMY_HISTORICTAX_ECON_PRICE
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedDiaMedica Therapeutics is a clinical-stage biopharmaceutical company. The earnings miss of $0.02 per share is small and the stock rose, indicating limited negative reaction. No specific product revenue or pipeline milestone was reported. The commercial mechanism is weak: the miss does not directly affect any commodity, supply chain, or margin for other firms. The impact is company-specific and minor.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- DiaMedica Therapeutics (NASDAQ: DMAC) reported Q1 2026 EPS loss of $0.19, missing consensus estimate of $0.17 by $0.02.
- Stock rose 4.3% to $6.52 on volume of 184,771 shares.
- Market cap $351.30 million, P/E ratio -9.31.
- Institutional ownership 10.12%; recent acquisitions by Bank of America Corp DE and Truvestments Capital LLC.
- Weiss Ratings 'sell (D-)'; five analysts 'Moderate Buy' with average target $12.33.